

Accepted Manuscript

GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight.

Heike Vogel, Stefanie Wolf, Cristina Rabasa, Francisca Rodriguez-Pacheco, Carina S. Babaei, Franziska Stöber, Jürgen Goldschmidt, Richard D. DiMarchi, Brian Finan, Matthias H. Tschöp, Suzanne L. Dickson, Annette Schürmann, Karolina P. Skibicka

PII: S0028-3908(16)30335-5

DOI: [10.1016/j.neuropharm.2016.07.039](https://doi.org/10.1016/j.neuropharm.2016.07.039)

Reference: NP 6398

To appear in: *Neuropharmacology*


Received Date: 12 February 2016

Revised Date: 26 July 2016

Accepted Date: 31 July 2016

Please cite this article as: Vogel, H., Wolf, S., Rabasa, C., Rodriguez-Pacheco, F., Babaei, C.S., Stöber, F., Goldschmidt, J., DiMarchi, R.D., Finan, B., Tschöp, M.H., Dickson, S.L., Schürmann, A., Skibicka, K.P., GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight., *Neuropharmacology* (2016), doi: 10.1016/j.neuropharm.2016.07.039.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight.

Running title: GLP-1-estrogen targets the SUM to alter food-reward behavior

Heike Vogel^{1,6,7}, Stefanie Wolf^{1,6}, Cristina Rabasa¹, Francisca Rodriguez-Pacheco¹, Carina S. Babaei¹, Franziska Stöber³, Jürgen Goldschmidt³, Richard D. DiMarchi⁴, Brian Finan^{5,7}, Matthias H. Tschöp^{5,7}, Suzanne L. Dickson¹, Annette Schürmann^{6,7}, Karolina P. Skibicka*²

¹Departments of Physiology/Endocrinology and ²Physiology/Metabolic Physiology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, SE-405 30 Gothenburg, Sweden; ³Department Systems Physiology of Learning, Leibniz Institute for Neurobiology, D-39120 Magdeburg, Germany; ⁴Department of Chemistry, Indiana University, Bloomington, IN 47405, USA; ⁵Institute for Diabetes and Obesity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH) and Technical University Munich, D-85748 Munich, Germany; ⁶Department of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbrücke, D-14558 Nuthetal, Germany; ⁷German Center for Diabetes Research, D-85764 Neuherberg, Germany

Corresponding author:

*Karolina P. Skibicka

Department of Physiology/Metabolic Physiology, Institute of Neuroscience and Physiology
The Sahlgrenska Academy at the University of Gothenburg, Medicinaregatan 11, PO Box 434,
SE-405 30 Gothenburg, Sweden

Email: Karolina.Skibicka@neuro.gu.se

Office: +46 31-786 3436

Fax: +46 31-786 3512

ABSTRACT

The obesity epidemic continues unabated and currently available pharmacological treatments are not sufficiently effective. Combining gut/brain peptide, GLP-1, with estrogen into a conjugate may represent a novel, safe and potent, strategy to treat diabetes. Here we demonstrate that the central administration of GLP-1-estrogen conjugate reduced food reward, food intake, and body weight in rats. In order to determine the brain location of the interaction of GLP-1 with estrogen, we avail of single-photon emission computed tomography imaging of regional cerebral blood flow and pinpoint a brain site unexplored for its role in feeding and reward, the supramammillary nucleus (SUM) as a potential target of the conjugated GLP-1-estrogen. We confirm that conjugated GLP-1 and estrogen directly target the SUM with site-specific microinjections. Additional microinjections of GLP-1-estrogen into classic energy balance controlling nuclei, the lateral hypothalamus (LH) and the nucleus of the solitary tract (NTS) revealed that the metabolic benefits resulting from GLP-1-estrogen injections are mediated through the LH and to some extent by the NTS. In contrast, no additional benefit of the conjugate was noted on food reward when the compound was microinjected into the LH or the NTS, identifying the SUM as the only neural substrate identified here to underlie the reward reducing benefits of GLP-1 and estrogen conjugate. Collectively we discover a surprising neural substrate underlying food intake and reward effects of GLP-1 and estrogen and uncover a new brain area capable of regulating energy balance and reward.

1.0 INTRODUCTION

The obesity epidemic continues unabated and is associated with adverse health consequences - diabetes, cardiovascular disease, disability, and increased cancer risk. The currently available pharmacological treatments are less efficient than expected. Therefore, there is an urgent need for novel therapies that reduce body weight more potently than currently available pharmaceuticals without producing undesirable side effects. One potential way to achieve a more potent weight loss may be by combining multiple anti-obesity drug targets in one molecule. Polypharmaceutical approaches, for example targeting the incretin system with a unimolecular glucagon-like peptide 1 (GLP-1)-estrogen co-agonist, offer promising solutions to treat diabetes (Finan et al., 2012).

GLP-1, a gut/brain peptide primarily produced in the intestinal tract in response to ingested nutrients and by the neurons of the nucleus of the solitary tract (NTS) of the brainstem (Holst, 2007), gained interest due to its glucoregulatory (Drucker, 2006) and appetite suppressing effects (Barrera et al., 2011). The highly selective GLP-1 receptor (GLP-1R) agonist, Exendin-4 (Ex4), is approved as antidiabetic agent in the treatment of type 2 diabetes (Byetta®) and anti-obesity treatment (Saxenda®). The steroid hormone estradiol, mainly produced by the ovaries, has also been implicated as a potential anti-obesity agent (Mauvais-Jarvis et al., 2013). However, the reproductive endocrine toxicity and oncogenicity limit its clinical application.

The conjugation of GLP-1 to estrogen allows for specific delivery of estrogen to GLP-1R expressing tissues without producing the undesirable side effects. In addition, this selective targeting of estrogen receptors to GLP-1R expressing cells is much more effective in reducing obesity and improving dyslipidemia and hyperglycemia than activation of either GLP-1 or estrogen receptors alone (Finan et al., 2012). The site of action of the weight and food intake reducing impact remains unknown. Here we hypothesize that the anti-obesity action of the conjugated GLP-1-estrogen is mediated by its direct action on CNS GLP-1 and estrogen receptors (ER), which are co-expressed in several brain areas regulating homeostatic feeding behavior and metabolism (Shughrue et al., 1997; Merchenthaler et al., 1999). Hedonically driven feeding may be one of the key components driving overeating (Berthoud, 2002, 2011, Alσιο et al., 2012). Furthermore the potential impact of the GLP-1-estrogen conjugate on food-reward behavior has not yet been explored.

In the present study we determine whether peripheral or central co-activation of GLP1 and estrogen receptors impacts on food-reward behavior. Using single-photon emission computed tomography (SPECT) imaging of regional cerebral blood flow (Kolodziej et al., 2014) and site-specific microinjections we identify the supramammillary nucleus (SUM), a brain area largely unexplored for its role in feeding or reward, as a potential target for the synergistic activity of the conjugate to regulate food reward. The latter finding not only reveals a surprising neural substrate underlying food intake and reward effects of GLP-1 and estrogen but also uncovers a new brain area capable of regulating energy balance and reward.

2.0 MATERIAL AND METHODS

2.1 Animals: Adult Sprague-Dawley rats (200-250 g, Charles River, Germany) were housed in a 12-hour light/dark cycle (lights on at 6 am) with regular chow and water available *ad libitum* in their home cages. All experiments were performed in male rats as the initial study by Finan et al. (2012) already demonstrated that the GLP-1-estrogen conjugate exerts the metabolic benefits independently of the gender. All animal procedures with rats were carried out with ethical permission and in accordance with the University of Gothenburg Institutional Animal Care and Use Committee guidelines. For functional neuroimaging adult eight week old male C57Bl/6 mice (Charles River, Germany) were used and studies were carried out in accordance with the German animal welfare laws and approved by the animal ethics committee of Sachsen-Anhalt.

2.2 Brain surgery: Brain cannulation was performed as previously described (Skibicka et al., 2011). Briefly, rats were implanted with a guide cannula under ketamine/xylazine anesthesia at the following coordinates: lateral ventricular guide cannula (26 gauge, Plastics One Roanoke, VA, USA; coordinates: ± 1.6 mm from midline, 0.9 mm posterior to bregma, and 2.5 mm ventral from the surface of the skull, with injector aimed 4.5 ventral to skull); ventral tegmental area (VTA) guide cannula (± 0.75 mm from midline, 5.7 mm posterior to bregma, and 6.5 mm ventral from the surface of the skull, with injector aimed 8.5 ventral to skull); (Skibicka et al., 2011); SUM guide cannula (on the midline, 4.7 mm posterior to bregma, and 7.1 mm ventral from the surface of the skull, with injector aimed 9.1 ventral to skull); lateral hypothalamus (LH) guide cannula (± 1.5 mm from midline, 2.8 mm posterior to bregma, and 6.8 mm ventral from the surface of the skull, with injector aimed 8.8 ventral to skull); NTS guide cannula (± 0.75 mm from midline, on occipital suture, and 6.9 mm ventral from the surface of the skull, with injector aimed 8.9 ventral to skull, modified from Richard et al. (2015); were attached to the skull with dental acrylic and jeweler's screws. Following a surgical recovery period (7 days) placement of the lateral ventricle cannula was verified by angiotensin II (2

μl ; 10 ng/ μl) administration. Rats, which consumed >5 ml/ water within 30 min following injection of angiotensin II were included in the studies. Correct placement of the VTA, LH and SUM cannula was confirmed *post mortem* by injection of India ink at the same microinjection volume as used for the experiment. NTS injection sites were evaluated by injection of 24 μg of 5-thio-d-glucose in 0.3 μl of aCSF, which induce a sympathoadrenal-mediated glycemic response if the injections correctly reach the NTS (Ritter et al., 1981). Only rats with correct placement were included in the study.

2.3 Drugs: GLP-1 control compound and GLP-1-estrogen stable conjugate were provided by R. DiMarchi (Indiana University, Bloomington, IN, USA). The conjugate is likely to target nuclear ER, both ER α and ER β may have a contribution since we previously demonstrated that both ER knockout mice have a blunted effect of the conjugate (Finan et al., 2012). The conjugate initiates the classic estrogen responsive element (ERE)-mediated transcriptional events, though a contribution from plasma membrane receptors cannot be excluded (especially considering the relatively rapid onset of the conjugate impact on reward). In the first study we confirmed that estrogen attachment does not influence the inherent activity of the peptide as the binding affinity and the biochemical signaling potency of the conjugate is similar to the parent peptides (Finan et al., 2012). This allows the ligand-activated endocytosis of GLP-1R at target cells and finally drives the intracellular transport of the conjugated estrogen to reach the intracellular receptors (Finan et al., 2012). We previously reported that for all metabolic parameters measured the stable conjugate offered an advantage compared to the GLP-1 compound alone, or compared to a labile conjugate, with a 7.5% weight loss in mice given the labile conjugate and 23% weight loss in mice that received the stable conjugate (Finan et al., 2012). Food intake followed the same pattern. Since the labile conjugate did not have any additional benefits over GLP-1 alone it was proposed that the efficacy of the conjugate likely relies on concentrating the estrogen into energy balance relevant tissues, since the estrogen is guided by GLP-1 and released intracellularly only in tissues expressing GLP-1 receptors. Importantly, the conjugate was not only designed to maximize the metabolic benefits above those of the single agonists but also to avoid the side effects often seen with GLP-1 activation and to bypass the reproductive endocrine toxicity and oncogenicity of estrogen (Finan et al., 2012). β -Estradiol was purchased from Sigma (E4389; St Louis, MO, US), dissolved in saline (vehicle for subcutaneous injections) or artificial cerebrospinal fluid (aCSF, Tocris, Bristol, UK, vehicle for central injections).

2.4 Operant conditioning procedure: To test the impact of GLP-1-estrogen on food-motivated behavior the sucrose-driven progressive ratio (PR) operant conditioning test was used. Food-induced operant conditioning training and testing were performed in rat conditioning chambers (30.5 x 24.1 x 21.0 cm; Med-Associates, Georgia, VT, USA) containing a metal grid floor, two retractable levers with light bulbs above, and a food pellet dispenser that can deliver 45 mg of sucrose pellets (Test Diet, Richmond, IN, USA). The training included four stages: first three sessions on fixed ratio (FR) starting

with FR1 (single press on the active lever = delivery of one sucrose pellet) followed by FR3 (3 presses/pellet) and finally FR5 (5 presses/pellet), where a minimum of 50 presses per session was required to graduate to the next FR level. The FR5 was followed by the PR schedule where the cost of a reward was progressively increased (Skibicka et al., 2011). PR sessions were continued until a stable baseline (15% for three consecutive sessions) was reached. During the FR and the first three PR sessions all rats were mildly food restricted resulting in a gradual loss of about 10% of their initial body weight over a period of one week.

For the drug testing the following conditions were used: (1) For subcutaneous (sc.) drug application (1 ml per kg body weight): vehicle, 2 µg GLP-1-estrogen, 1.87 µg GLP-1, and 0.13 µg estrogen per kg body weight. (2) For intracerebroventricular (ICV) drug application (1 µl): vehicle, 0.125 µg GLP-1-estrogen, 0.117 µg GLP-1, and 0.008 µg estrogen. (3) For VTA (0.5 µl), and SUM (0.3 µl) drug application: vehicle, 0.075 µg GLP-1-estrogen, 0.07 µg GLP-1, and 0.005 µg estrogen. Satiated rats received the injections early in the light phase 90 min (sc. injections) or 30 min (central injections) before the 60 min sucrose reinforced PR operant conditioning.

2.5 SPECT-imaging of regional cerebral blood flow: SPECT-imaging of rCBF was performed similarly as described in detail in Kolodziej et al. (2014). In brief, awake unrestrained C57Bl/6J mice were intravenously injected via jugular vein catheters with the blood flow tracer 99m-technetium hexamethylpropyleneamine oxime (99mTc-HMPAO) after treatment with GLP-1-estrogen, GLP-1, or PBS as control. After 99mTc-HMPAO-injection animals were anesthetized and scanned using a small-animal SPECT/CT scanner. 99mTc-HMPAO is a lipophilic compound that, after flow-dependent wash-in, is rapidly converted to a hydrophilic compound that remains trapped in the brain and shows no redistribution. The 99mTc-brain distribution as determined in anesthetized animals in the scanner thus reflects the spatial pattern of the average blood flow during the injection period in the awake state. Jugular vein catheters (ALZET, Cupertino, USA; 44.5 mm PU, OD: 0.84 mm, ID: 0.36 mm, connected to a 50 mm ALZET connection, OD: 1.02 mm OD, ID: 0.61 mm, total catheter length 9.5 cm) were implanted into the right external jugular vein. Following a two days recovery period, mice were intraperitoneally injected either with 400 µg per kg body weight (1 ml per kg body weight) GLP-1 (n=8), GLP-1-estrogen (n=7), or PBS (n=7). After substance application the jugular vein catheter was connected via a saline-filled Teflon tube (Tefzel-Tube, CS-Chromatographie Service GmbH, D-52379 Langerwehe, Germany, OD: 1/16 inch ID: 0.5 mm) of 60 length to a saline filled syringe. 30 min after substance application a syringe filled with the 99mTc-HMPAO-injection solution was connected to the Teflon tube and the tracer injection started. 99mTc-HMPAO was freshly prepared from frozen aliquots of kit preparations for use in humans (Ceretek™, GE-Healthcare, Buchler, Braunschweig, Germany) (Kolodziej et al., 2014). Compared to the previous study (Kolodziej et al., 2014) the HMPAO-concentration in the aliquots was doubled so that the volumes of the aliquots could be

reduced (125 μ l as compared to 250 μ l). Injections were made using a syringe pump (Harvard Instruments, Holliston, MA, USA). The tracer was injected over 18 ± 2 min. In principle, the tracer can be injected in much shorter time periods (Kolodziej et al., 2014). We here hypothesized that averaging blood flow over longer periods of time might be a more suitable approach for visualizing longer-lasting drug effects. The animals were injected with ^{99m}Tc -HMPAO-solutions in volumes of 340 ± 83 μ l, the differences in volume being due to variations in ^{99m}Tc -contents in the eluate from the ^{99m}Tc -generators. The flow rate of the tracer-infusion pump was adjusted according to the differing volumes (16 μ l to 25 μ l/min) of the tracer-solutions. After tracer injection, animals were anesthetized with 2% isoflurane and transferred to the SPECT/CT-scanner (four-head NanoSPECT/CTTM Mediso / Hungary). The amounts of ^{99m}Tc remaining in the syringe, and teflon tube were determined using a radionuclide calibrator (Aktivimeter Isomed 2010, Nuklear-Medizin-Technik Dresden GmbH, Germany) and subtracted from the initial activity of the tracer solution to calculate the injected dose. The animals were injected on average with 60 ± 8 MBq of ^{99m}Tc .

For SPECT/CT imaging mice were scanned under gas anesthesia (1.0 - 1.5% isoflurane in 2:1 O₂:N₂O volume ratio). CT and SPECT images were co-registered. CT scans were made at 45 kVp, 177 μ A, with 180 projections, 500 msec per projections, 96 μ m isotropic spatial resolutions, and reconstructed with the manufacturer's software (InVivoScope 1.43) at isotropic voxel-sizes of 100 μ m. SPECT scans were made using ten-pinhole mouse brain apertures with 1.0 mm pinhole diameters providing an isotropic spatial resolution of about 0.7 mm FWHM (Kolodziej et al., 2014). 24 projections were acquired during a total scan time of 2 hours. Axial FOV was 20.9 mm. Energy windows were set to the default values of the NanoSPECT/CT (140 keV +/- 5%). SPECT images were reconstructed using the iterative algorithm of the manufacturer's software (HiSPECTTM, SCIVIS, Goettingen) at isotropic voxel output sizes of 338 μ m.

For data analysis brain ^{99m}Tc -distributions were compared in mice injected with PBS; GLP-1, or GLP-1-estrogen. SPECT/CT images were manually aligned to a high-resolution MR mouse brain data set (Ma et al., 2005) based on skull-landmarks of the CTs using the MPI-ToolTM software (version 6.36, ATV, Advanced Tomo Vision, D-50169 Kerpen, Germany). SPECT brain data were cut out of the SPECT-data in the OsirixTM DICOM-viewer (64-bit version 5.7.1) using a whole-brain volume-of-interest (VOI) made from the template provided by Ma and colleagues (Ma et al., 2005). Brain SPECT data were global mean normalized using the MPI-ToolTM software. In the voxelwise analysis unpaired t-tests were made to compare brain tracer distributions in PBS versus GLP-1 and GLP-1-estrogen using the MagnAn-software (version 2.4, BioCom GbR, D-90180 Uttenreuth, Germany). Following common procedures in small-animal radionuclide imaging (Endepols et al., 2010; Wyckhuys et al., 2010; Thanos et al., 2013) uncorrected p-values were used. As a major result at the level of $p < 0.01$ we found when testing GLP-1-estrogen against PBS a deactivation in a mid-rostrocaudal part of the

cingulate cortex and a prominent activation centered on the SUM. Illustrations of the results were made in Osirix™. Images in Osirix™ were exported as TIFF files and arranged using the Photoshop™ software (version CS4).

In order to calculate the differences in mean tracer uptake in the volume covered by the $p < 0.01$ voxels in the SUM-region in the probability maps, significant voxels from GLP-1-estrogen versus PBS injection extending from Bregma -2.1 to -2.8 according to Franklin and Paxinos (George Paxinos, 2012) were grouped to one VOI using the Plugin function "Growing region" in Osirix™. Compared to the PBS-group mean tracer uptake in this VOI increased by 12% in the GLP-1-estrogen group and by 6% in the GLP-1 group.

2.6 Chow intake and body weight: Immediately after operant testing rats were moved to their home cages and 1h and 24h chow intake was measured. Body weight was determined immediately before the injection and 24h postinjection.

2.7 Pica response: To investigate whether GLP-1 injection induces malaise, the intake of kaolin (Research Diets, Lane New Brunswick, NJ, USA) (Mitchell et al., 1976), a non-nutritive substance, was measured in parallel to chow intake measurements. All rats were exposed to kaolin before the experimental injections.

2.8 Locomotor activity: For activity measurements rats were injected centrally (ICV) with vehicle, GLP-1-estrogen, GLP-1 or estrogen, placed into the activity chamber 30 min later and spontaneous horizontal activity was recorded for 60 min. Rats had no access to food during the test.

2.9 Statistical analysis: For statistical analysis all parameters were initially tested with Levene's statistics for homogeneity of variances. At equal variances data were analyzed by repeated measures analysis of variance (ANOVA) followed by *post hoc* Bonferroni test. If the variances were not homogeneous parameters were analyzed using the Generalized Linear Model. All statistical analyses were conducted using the SPSS software. A p -value < 0.05 was considered significant and values are expressed as means \pm SEM, unless otherwise stated.

3.0 RESULTS AND DISCUSSION

3.1 Subcutaneous co-activation of GLP-1 and estrogen receptors reduces body weight and food reward.

Given the initial data of Finan et al., (2012) demonstrating the anorexigenic properties of the GLP-1-estrogen conjugate in mice we first tested whether peripheral injection of GLP-1-estrogen in rats can similarly reduce food intake and body weight. In rats, a single peripheral, s.c., injection of GLP-1-estrogen (2 μ g/kg) significantly decreased body weight and 24h food

intake (Figure 1a,b), whereas 1h chow intake was unaltered in all groups (data not shown). The equimolar doses of GLP-1 or estrogen alone were subthreshold for the anorexic effect, indicating a synergistic effect of GLP-1-estrogen combination. The reduced feeding response in GLP-1-estrogen treated animals was not accompanied by the induction of a malaise response, as the ingestion of kaolin (a pica response) was similar in all compared groups 24h postinjection (Figure 1b). We have previously shown that in mice the weight loss after the conjugate administration is primarily due to fat loss (Finan et al., 2012). While water intake was not measured in the current study, recent literature suggests it is possible that GLP-1 alone reduces water intake (McKay et al., 2011, McKay and Daniels, 2013) in addition to reducing food intake, it is less likely, however, that the conjugate further reduced water intake since to date the water intake reducing effects of estrogen were primarily seen in females (Santollo and Daniels, 2015), and the current study is performed in males. Furthermore the conjugate is equally effective at reducing body weight in males and females (Finan et al., 2012).

GLP-1 effects on body weight regulation and feeding are largely mediated by the CNS. Recent literature demonstrates that peripheral or central application of GLP-1 or GLP-1 analogs into the VTA, NAc, NTS, or parabrachial nucleus alters food-reward behavior (Dickson et al., 2012; Alhadeff et al., 2014; Richard et al., 2015). NTS GLP-1-producing neurons project directly to the mesolimbic VTA and NAc (Rinaman, 2010; Dossat et al., 2011; Alhadeff et al., 2012; Dickson et al., 2012). So far the impact of estrogen on food-motivated behavior is largely unknown. To determine whether the GLP-1-estrogen conjugate can change the motivational value of palatable food, a correlate of food-reward behavior (HODOS, 1961), we examined the number of sucrose rewards earned under a progressive ratio (PR) reinforcement schedule after peripheral, s.c., administration of the GLP-1, estrogen or the conjugate of the two. Conjugate-injected rats reduced food-motivated behavior to a greater extent than rats treated with vehicle, estrogen, or GLP-1 alone as the number of active-lever presses (Figure 1c) and sucrose pellets earned (Figure 1d) were significantly decreased. Taken together these data demonstrate a new role for conjugating GLP-1 with estrogen in regulation of food reward. The potentiated reward-suppression of these two substances applied together is in line with recent findings demonstrating that estrogen is a critical regulator of the impact of a GLP-1 analogue, exendin-4, on food reward in both males and females (Richard et al., 2016).

3.2 Central co-activation of GLP-1 and estrogen receptor is sufficient to decrease food intake and food reward.

Central activation of GLP-1R reduces food intake, whereas central GLP-1R blockade induces hyperphagia (Tang-Christensen et al., 1996; Turton et al., 1996; Schick et al., 2003). Several studies documented that estradiol (E2) suppresses food intake via central ER α and ER β (Heine et al., 2000; Geary et al., 2001; Asarian and Geary, 2002; Liang et al., 2002; Gao et al., 2007). Here we demonstrate that central, ICV, application of GLP-1-estrogen was sufficient to reproduce the effect of peripheral injection on body weight and chow intake (Figure 2a,c), whereas 1h food intake was unaffected (Figure 2b). Conjugate injection was more effective at reducing body weight and food intake than estrogen alone and tended to be more potent in comparison to GLP-1, though this difference did not reach significance. The significantly reduced 24h chow intake after central injection of GLP-1-estrogen or GLP-1 was not accompanied by a malaise response (Figure 2c). We then examined whether central co-activation of GLP-1 and estrogen receptors affects food-motivated behavior. Acute central GLP-1-estrogen treatment significantly reduced operant PR response for sucrose, whereas the equimolar doses of GLP-1 or estrogen failed to reduce food reward when applied individually (Figure 2d,e). Moreover, in a separate experiment, GLP-1 or GLP-1-estrogen did not affect general locomotor activity at doses that significantly reduced chow intake and food-motivated behavior (Figure 2f). These data support a role of the CNS in mediating GLP-1-estrogen effects on food intake and reward. We additionally show for the first time that the beneficial metabolic effects of GLP-1 and estrogen stimulation are not necessarily accompanied by general locomotor impairment or malaise, side-effects often seen with GLP-1 activation in rodents or humans, at the doses used in the study (Turton et al., 1996; Seeley et al., 2000; Kinzig et al., 2002; Madsbad et al., 2011; Dickson et al., 2012). It is of course possible that the results obtained would differ if higher doses of the conjugate or GLP-1 were used than those applied in the current study.

3.3 The supramammillary nucleus (SUM) is a direct target site for GLP-1-estrogen actions on body weight, food intake, and food-motivated behavior

To find the CNS-sites underlying GLP-1-estrogen driven food reward changes we used a recently developed SPECT-imaging of regional cerebral blood flow (Kolodziej et al., 2014) as

a screening tool. The voxelwise analysis revealed significant differences in rCBF after intraperitoneal injection of GLP-1-estrogen, and GLP-1 in contrast to vehicle-treated animals at $p < 0.001$ (Figure 3 and Supplementary Figure 1). The ^{99m}Tc brain uptake was significantly increased after GLP-1-estrogen injection in an area extending from the SUM to the posterior hypothalamus and substantia nigra and was significantly reduced in the cingulate area as compared to vehicle injections (Figure 3a and Supplementary Figure 1a). Few significant voxels were also detected in the left primary somatosensory cortex and left dorsal thalamus indicating reduced rCBF after GLP-1-estrogen injection in these regions (Supplementary Figure 1b). After injection of GLP-1 the ^{99m}Tc brain uptake was found to be significantly reduced in the left entorhinal/entorhinal area and in few voxels within the primary somatosensory cortex (Supplementary Figure 1c,d). Isolated voxels indicating increased rCBF after injection of GLP-1 were found in the right amygdala, cingulum/anterior cingulate area and left superior colliculus (Supplementary Figure 1c,d). If the significance level is increased to $p < 0.01$, a significant increase in rCBF was also found in the SUM and posterior hypothalamus after GLP-1 injection alone (Figure 3b). VOI analysis, representing the mean differences within the SUM/posterior hypothalamus after injection of GLP-1-estrogen, GLP-1, or vehicle obtained from added global mean normalized data of single animals, revealed an increase in ^{99m}Tc uptake in this region from vehicle injection (1.10μ) to GLP-1 injection (1.17μ) and to GE injection (1.25μ) of about 6% in each case (Figure 3c,d). Thus, SPECT-imaging revealed the SUM as the main GLP-1-estrogen target area. The SUM is rather unexplored in the fields of energy balance regulation or reward. Nevertheless, a few studies have suggested that the SUM may participate in reward and feeding control. The medial part of SUM contains dopamine neurons and receives dense projections from the LH, including LH orexin neurons (Peyron *et al.*, 1998; Swanson, 1982). Administration of GABA_A receptor antagonists into the SUM potently induces intracranial drug self-administration. This nucleus also mediates reward triggered by administration of nicotine or the glutamate receptor agonist AMPA (Ikemoto *et al.*, 2004, 2006). ER β , GPR30, and GLP-1R have been detected in the SUM (Shughrue *et al.*, 1997; Merchenthaler *et al.*, 1999; Hazell *et al.*, 2009) suggesting a potential for a direct effect of the GLP-1-estrogen in this area. GLP-1-estrogen injections into the SUM performed next further supported this idea as the sucrose-driven food reward and chow intake after GLP-1-estrogen administration were reduced to a much greater extent than by estrogen or GLP-1 alone (Figure 4a-d). It is impossible to entirely exclude the

possibility that some injection fluid also reached the VTA, the neighboring structure that co-express GLP-1 and estrogen receptors (Shughrue et al., 1997; Merchenthaler et al., 1999). However, current results demonstrate that the conjugate is ineffective at the level of the VTA (Figure 4f). The administration of GLP-1 alone into the VTA resulted in a significant suppression of food reward, which is consistent with previous findings (Dickson et al., 2012). Thus we show that, surprisingly, traditional reward-controlling areas do not contribute to the reward-suppressing effect of the conjugated GLP-1 with estrogen but instead discover a novel candidate area, the SUM, to underlie the reward-reducing impact of GLP-1-estrogen. Since both, GLP-1 and estrogen receptors, are present in the SUM and direct intra-SUM microinjections of GLP-1-estrogen potently suppressed food reward it is reasonable to conclude that the molecule hybrid targets the reward system through a direct action in the SUM. Accordingly we demonstrate that brain circuitry beyond the classical mesolimbic dopaminergic system drives food-motivated behavior and place the SUM on the food reward regulation map certainly warranting future studies on the role of this nucleus in regulation of food reward.

3.4 GLP-1-estrogen enhances the metabolic benefits when injected into the LH and the NTS

Since both, GLP-1R and ER, are also co-expressed in more classical energy balance regulating areas (Shughrue et al., 1997; Merchenthaler et al., 1999) we determined whether these sites comprise the CNS target sites of GLP-1-estrogen actions on energy homeostasis. The compounds were microinjected into the LH and the NTS; brain areas associated with feeding behavior control (Schwartz, 2006; Simpson et al., 2009). The LH was a highly sensitive target site for the body weight reduction of the conjugate (Figure 5a). Although the NTS GLP-1-estrogen injections failed to reach significance there was an obvious trend ($p=0.16$) to body weight reduction. In addition targeting of the LH and NTS with the GLP-1-estrogen compound induced a robust reduction in 24h feeding response (Figure 5b). Moreover, in both cases conjugate injection was more efficacious at lowering body weight and food intake than either GLP-1 or estrogen alone. Thus, by site-specific injections we demonstrate that the LH and to some extent the NTS are involved in GLP-1-estrogen synergy on food intake and body weight regulation. These results are in line with previous literature suggesting these two brain nuclei are key neural substrates for energy balance effects of GLP-1. Direct administration of GLP-1 into the LH significantly reduces food intake, whereas injection of

Ex9 increases food intake (McMahon and Wellman, 1998; Schick et al., 2003) indicating a physiological role of GLP-1R in this area in feeding behavior control.

In addition, neuronal processing restricted to the NTS was also sufficient to mediate the intake-suppressive effects of the conjugate. The NTS is the first central area processing the gastrointestinal signals to the brain. Vagal-afferent signals synapse in specific subnuclei within the NTS to regulate food intake (Schwartz, 2000). Direct NTS injections of Ex9 or knockdown of preproglucagon, the precursor of GLP-1, in the NTS causes hyperphagia and weight gain (Hayes et al., 2009; Barrera et al., 2011). Activation of GLP-1R in the NTS, by direct injection of GLP-1 or Ex4, reduces both food intake and engages NTS noradrenergic neurons (Richard et al., 2015). Also estrogen can act via ER α on NTS neurons to inhibit feeding (Asarian and Geary, 2007; Thammacharoen et al., 2008). Current data indicating a potent food-intake reduction after intra-NTS conjugate infusion are in line with these previous studies showing a role for both GLP-1 and estrogen in NTS in food intake regulation. That both hindbrain and hypothalamic nuclei have a key contribution to the anorexic properties of GLP-1-estrogen is perhaps not surprising considering that the neural control of energy balance is distributed across the neuraxis and many food intake regulating signals exert a similar effect from several CNS sites (Grill, 2006; Skibicka and Grill, 2009; Kanoski et al. 2016). We also note that the SUM, LH and NTS may not be the only neural substrates targeted by the conjugate, and further studies examining more metabolic parameters (for example blood glucose changes) and different time points may reveal additional neural targets. One such possible target is the arcuate nucleus, suggested to be an important mediator of food intake effects of GLP-1R activation by some studies (Beiroa et al., 2014)(Secher et al., 2014), or an important mediator of blood glucose changes induced by GLP-1 by other studies (Sandoval et al., 2008).

Recent literature demonstrates that peripheral or central application of GLP-1 or GLP-1 analogs into the VTA, NAc, NTS, or parabrachial nucleus alters food-reward behavior (Dickson et al., 2012; Alhadeff et al., 2014; Richard et al., 2015). NTS GLP-1-producing neurons project directly to the mesolimbic VTA (Rinaman, 2010; Dossat et al., 2011; Alhadeff et al., 2012; Dickson et al., 2012). So far the impact of estrogen on food-motivated behavior is largely unknown. Nevertheless, a wide range of behaviors and neurobiological mechanisms are modulated by estrogen, including alterations in a conditioned place preference test and the neuroprotection of dopamine cells (Küppers et al., 2000; Walf et al.,

2007). In the current study microinjections of GLP-1-estrogen into the traditional reward-associated area, the VTA, failed to show a synergistic effect of the conjugate in food-motivated behavior changes. Thus we speculated that, in addition to SUM, the LH may be another good candidate neural substrate for the GLP-1-estrogen impact on food reward since the LH also regulates reward behavior and serves as an interface between the hypothalamus and the mesolimbic system (Geisler and Zahm, 2005; Teitelbaum and Epstein, 1962; Thompson and Swanson, 2010). While microinjections into the LH revealed a significantly suppressed food reward by GLP-1-estrogen, GLP-1 alone reduced reward to the same level (Figure 5c) indicating that estrogen and GLP-1 do not synergise to reduce food reward in the LH. Similar results were obtained with the intra-NTS microinjections, indicating that consistent with previous studies (Alhadeff and Grill, 2014, Richard et al., 2015) NTS is an important brain nucleus for GLP-1-induced reward suppression, but does not play a role in the interaction of GLP-1 and estrogen to reduce food reward. These results highlight the differential responsivity of different neural substrates to the conjugate, and show that only select sites mediate the synergistic effects of the conjugate. Thus it is possible that our effect in ventricle-injected animals gets diluted since it provides access to many GLP-1 expressing sites, many of which may not participate in the added benefit of combining GLP-1 with estrogen, in contrast to the injection performed at other sites (eg SUM).

In summary, microinjections into key energy balance controlling nuclei revealed that the metabolic benefits resulting from GLP-1-estrogen injections are mediated through the LH and to some extent by the NTS. In contrast, no additional benefit of the conjugate was noted on food reward when the compound was microinjected into the LH or the NTS, leaving the SUM as the only neural substrate identified here to underlie the reward reducing benefits of GLP-1 and estrogen conjugate.

3.5 Conclusions

In conclusion, the data presented here provide clear evidence that the CNS is a crucial target for GLP-1-estrogen mediated actions on energy homeostasis and outline a previously unidentified role of this compound on food reward. These new insights into the mechanisms of the combined GLP-1 and estrogen action highlight the therapeutic potential of a new class of polypharmaceutical agents for the treatment of the metabolic syndrome. To localize the

site of GLP-1-estrogen synergy on food reward we used a novel approach of functional neuroimaging. An important and unexpected finding of the present study is that coactivation of GLP-1 and estrogen receptors results in a unique activation of SUM, brain area clearly capable of regulating energy balance and reward that has not been previously indicated for this role. These findings may be clinically relevant, since peripheral injections, the application route used in diabetic and obese patients prescribed GLP-1-based drugs, activated the SUM.

4.0 ACKNOWLEDGEMENTS

This work was supported by the Novo Nordisk Foundation Excellence project grant (KPS), Ragnar Söderberg Foundation (KPS), Swedish Research Council (2014-2945 to KPS, 2013-7107 to PR and 2012-1758 to SLD), German Research Foundation, DFG (HV), German Center for Diabetes Research (01GI0922, AS, HV), and EC Grants Full4Health (266408, SLD, KPS) and Nudge-it (607310, SLD). We gratefully thank Robert Jakubowicz for technical assistance. RDD was a cofounder of Marcadia Biotech. The authors declare no competing financial interests.

5.0 REFERENCES

- Alhadeff AL, Baird J-P, Swick JC, Hayes MR, Grill HJ (2014) Glucagon-like Peptide-1 receptor signaling in the lateral parabrachial nucleus contributes to the control of food intake and motivation to feed. *Neuropsychopharmacology* 39:2233–2243.
- Alhadeff AL, Grill HJ (2014) Hindbrain nucleus tractus solitarius glucagon-like peptide-1 receptor signaling reduces appetitive and motivational aspects of feeding. *American journal of physiology Regulatory, integrative and comparative physiology* 307:R465-470.
- Alhadeff AL, Rupprecht LE, Hayes MR (2012) GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. *Endocrinology* 153:647–658.
- Alhadeff AL, Grill HJ (2014) Hindbrain nucleus tractus solitarius glucagon-like peptide-1 receptor signaling reduces appetitive and motivational aspects of feeding. *American journal of physiology Regulatory, integrative and comparative physiology* 307:R465-470.
- Alsio J, Olszewski PK, Levine AS, Schioth HB (2012) Feed-forward mechanisms: addiction-like behavioral and molecular adaptations in overeating. *Frontiers in neuroendocrinology* 33:127-139.
- Santollo J, Daniels D (2015) Control of fluid intake by estrogens in the female rat: role of the hypothalamus. *Frontiers in systems neuroscience* 9:25.
- Secher A, Jelsing J, Baquero AF, Hecksher-Sorensen J, Cowley MA, Dalboge LS, Hansen G, Grove KL, Pyke C, Raun K, Schaffer L, Tang-Christensen M, Verma S, Witgen BM, Vrang N, Bjerre Knudsen L (2014) The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. *The Journal of clinical investigation* 124:4473-4488.
- Asarian L, Geary N (2002) Cyclic estradiol treatment normalizes body weight and restores physiological patterns of spontaneous feeding and sexual receptivity in ovariectomized rats. *Horm Behav* 42:461–471.
- Asarian L, Geary N (2007) Estradiol enhances cholecystokinin-dependent lipid-induced satiation and activates estrogen receptor-alpha-expressing cells in the nucleus tractus solitarius of ovariectomized rats. *Endocrinology* 148:5656–5666.

- Barrera J, Sandoval D, D'Alessio D, Seeley R (2011) GLP-1 and energy balance: an integrated model of short-term and long-term control. *Nat Rev Endocrinol* 7:507–516.
- Berthoud HR (2002) Multiple neural systems controlling food intake and body weight. *Neuroscience and biobehavioral reviews* 26:393-428.
- Berthoud HR (2011) Metabolic and hedonic drives in the neural control of appetite: who is the boss? *Current opinion in neurobiology* 21:888-896.
- Beiroa D, Imbernon M, Gallego R, Senra A, Herranz D, Villarroya F, Serrano M, Ferno J, Salvador J, Escalada J, Dieguez C, Lopez M, Fruhbeck G, Nogueiras R (2014) GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. *Diabetes* 63:3346-3358.
- Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP (2012) The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors. *J Neurosci* 32:4812–4820.
- Dossat AM, Lilly N, Kay K, Williams DL (2011) Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. *J Neurosci* 31:14453–14457.
- Drucker DJ (2006) The biology of incretin hormones. *Cell Metab* 3:153–165.
- Endepols H, Sommer S, Backes H, Wiedermann D, Graf R, Hauber W (2010) Effort-based decision making in the rat: an [18F]fluorodeoxyglucose micro positron emission tomography study. *J Neurosci* 30:9708–9714.
- Finan B et al. (2012) Targeted estrogen delivery reverses the metabolic syndrome. *Nat Med* 18:1847–1856.
- Gao Q, Mezei G, Nie Y, Rao Y, Choi CS, Bechmann I, Leranth C, Toran-Allerand D, Priest CA, Roberts JL, Gao X-B, Mobbs C, Shulman GI, Diano S, Horvath TL (2007) Anorectic estrogen mimics leptin's effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals. *Nat Med* 13:89–94.

- Geary N, Asarian L, Korach KS, Pfaff DW, Ogawa S (2001) Deficits in E2-dependent control of feeding, weight gain, and cholecystokinin satiation in ER-alpha null mice. *Endocrinology* 142:4751–4757.
- Geisler S, Zahm DS (2005) Afferents of the ventral tegmental area in the rat-anatomical substratum for integrative functions. *J Comp Neurol* 490:270–294.
- George Paxinos KF (2012) Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates. São Paulo, Acad Press:360 p.
- Grill HJ (2006) Distributed neural control of energy balance: contributions from hindbrain and hypothalamus. *Obesity (Silver Spring)* 14 Suppl 5:216S – 221S.
- Hayes MR, Bradley L, Grill HJ (2009) Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. *Endocrinology* 150:2654–2659.
- Hazell GGJ, Yao ST, Roper JA, Prossnitz ER, Carroll AM, Lolait SJ (2009) Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues. *J Endocrinol* 202:223–236.
- Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS (2000) Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. *Proc Natl Acad Sci U S A* 97:12729–12734.
- Hodos W (1961) Progressive ratio as a measure of reward strength. *Science* 134:943–944.
- Holst JJ (2007) The physiology of glucagon-like peptide 1. *Physiol Rev* 87:1409–1439.
- Ikemoto S, Qin M, Liu Z-H (2006) Primary reinforcing effects of nicotine are triggered from multiple regions both inside and outside the ventral tegmental area. *J Neurosci* 26:723–730.

- Ikemoto S, Witkin BM, Zangen A, Wise RA (2004) Rewarding effects of AMPA administration into the supramammillary or posterior hypothalamic nuclei but not the ventral tegmental area. *J Neurosci* 24:5758–5765.
- Kinzig KP, D'Alessio DA, Seeley RJ (2002) The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. *J Neurosci* 22:10470–10476.
- Kolodziej A, Lippert M, Angenstein F, Neubert J, Pethe A, Grosser OS, Amthauer H, Schroeder UH, Reymann KG, Scheich H, Ohl FW, Goldschmidt J (2014) SPECT-imaging of activity-dependent changes in regional cerebral blood flow induced by electrical and optogenetic self-stimulation in mice. *Neuroimage* 103:171–180.
- Küppers E, Ivanova T, Karolczak M, Beyer C (2000) Estrogen: A multifunctional messenger to nigrostriatal dopaminergic neurons. *J Neurocytol* 29:375–385.
- Liang Y-Q, Akishita M, Kim S, Ako J, Hashimoto M, Iijima K, Ohike Y, Watanabe T, Sudoh N, Toba K, Yoshizumi M, Ouchi Y (2002) Estrogen receptor beta is involved in the anorectic action of estrogen. *Int J Obes Relat Metab Disord* 26:1103–1109.
- Livak KJ, Schmittgen TD (2001) Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2- $^{-\Delta\Delta CT}$ Method. *Methods* 25:402–408.
- Ma Y, Hof PR, Grant SC, Blackband SJ, Bennett R, Slatest L, Mcguigan MD, Benveniste H (2005) A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy. *Neuroscience* 135:1203–1215.
- Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ (2011) An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future. *Diabetes Obes Metab* 13:394–407.
- Mauvais-Jarvis F, Clegg DJ, Hevener AL (2013) The role of estrogens in control of energy balance and glucose homeostasis. *Endocr Rev* 34:309–338.
- McMahon LR, Wellman PJ (1998) PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. *Am J Physiol* 274:R23–R29.

- McKay NJ, Daniels D (2013) Glucagon-like peptide-1 receptor agonist administration suppresses both water and saline intake in rats. *Journal of neuroendocrinology* 25:929-938.
- McKay NJ, Kanoski SE, Hayes MR, Daniels D (2011) Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake. *American journal of physiology Regulatory, integrative and comparative physiology* 301:R1755-1764.
- Merchenthaler I, Lane M, Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. *J Comp Neurol* 403:261-280.
- Mitchell D, Wells C, Hoch N, Lind K, Woods SC, Mitchell LK (1976) Poison induced pica in rats. *Physiol Behav* 17:691-697.
- Olofsson LE, Pierce AA, Xu AW (2009) Functional requirement of AgRP and NPY neurons in ovarian cycle-dependent regulation of food intake. *Proc Natl Acad Sci U S A* 106:15932-15937.
- Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. *J Neurosci* 18:9996-10015.
- Quarta D, Di Francesco C, Melotto S, Mangiarini L, Heidbreder C, Hedou G (2009) Systemic administration of ghrelin increases extracellular dopamine in the shell but not the core subdivision of the nucleus accumbens. *Neurochem Int* 54:89-94.
- Richard JE, Anderberg RH, Göteson A, Gribble FM, Reimann F, Skibicka KP (2015) Activation of the GLP-1 Receptors in the Nucleus of the Solitary Tract Reduces Food Reward Behavior and Targets the Mesolimbic System. *PLoS One* 10:e0119034.
- Richard JE, Anderberg RH, Lopez-Ferreras L, Olandersson K, Skibicka KP (2016) Sex and estrogens alter the action of glucagon-like peptide-1 on reward. *Biology of sex differences* 7:6.

- Richard JE, Anderberg RH, Goteson A, Gribble FM, Reimann F, Skibicka KP (2015) Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system. *PLoS one* 10:e0119034.
- Richard JE, Anderberg RH, Lopez-Ferreras L, Olandersson K, Skibicka KP (2016) Sex and estrogens alter the action of glucagon-like peptide-1 on reward. *Biology of sex differences* 7:6.
- Rinaman L (2010) Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure. *Brain Res* 1350:18–34.
- Ritter RC, Slusser PG, Stone S (1981) Glucoreceptors controlling feeding and blood glucose: location in the hindbrain. *Science* 213:451–452.
- Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ (2008) Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. *Diabetes* 57:2046–2054.
- Santollo J, Daniels D (2015) Control of fluid intake by estrogens in the female rat: role of the hypothalamus. *Frontiers in systems neuroscience* 9:25.
- Schick RR, Zimmermann JP, vom Walde T, Schusdziarra V (2003) Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. *Am J Physiol Regul Integr Comp Physiol* 284:R1427–R1435.
- Schwartz GJ (2000) The role of gastrointestinal vagal afferents in the control of food intake: Current prospects. In: *Nutrition*, pp 866–873.
- Schwartz GJ (2006) Integrative capacity of the caudal brainstem in the control of food intake. *Philos Trans R Soc Lond B Biol Sci* 361:1275–1280.
- Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, Hansen G, Grove KL, Pyke C, Raun K, Schäffer L, Tang-Christensen M, Verma S, Witgen BM, Vrang N, Bjerre Knudsen L (2014) The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. *J Clin Invest* 124:4473–4488.

- Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC, D'Alessio D (2000) The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. *J Neurosci* 20:1616–1621.
- Shughrue PJ, Lane M V, Merchenthaler I (1997) Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. *J Comp Neurol* 388:507–525.
- Simpson KA, Martin NM, Bloom SR (2009) Hypothalamic regulation of food intake and clinical therapeutic applications. *Arq Bras Endocrinol Metabol* 53:120–128.
- Skibicka KP, Grill HJ (2009) Hypothalamic and hindbrain melanocortin receptors contribute to the feeding, thermogenic, and cardiovascular action of melanocortins. *Endocrinology* 150:5351–5361.
- Skibicka KP, Hansson C, Alvarez-Crespo M, Friberg PA, Dickson SL (2011) Ghrelin directly targets the ventral tegmental area to increase food motivation. *Neuroscience* 180:129–137.
- Swanson LW (1982) The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. *Brain Res Bull* 9:321–353.
- Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Møller M, Sheikh SP (1996) Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. *Am J Physiol* 271:R848–R856.
- TEITELBAUM P, EPSTEIN AN (1962) The lateral hypothalamic syndrome: recovery of feeding and drinking after lateral hypothalamic lesions. *Psychol Rev* 69:74–90.
- Thammacharoen S, Lutz TA, Geary N, Asarian L (2008) Hindbrain administration of estradiol inhibits feeding and activates estrogen receptor- α -expressing cells in the nucleus tractus solitarius of ovariectomized rats. *Endocrinology* 149:1609–1617.

- Thanos PK, Robison L, Nestler EJ, Kim R, Michaelides M, Lobo M-K, Volkow ND (2013) Mapping brain metabolic connectivity in awake rats with μ PET and optogenetic stimulation. *J Neurosci* 33:6343–6349.
- Thompson RH, Swanson LW (2010) Hypothesis-driven structural connectivity analysis supports network over hierarchical model of brain architecture. *Proc Natl Acad Sci U S A* 107:15235–15239.
- Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. *Nature* 379:69–72.
- Walf AA, Rhodes ME, Meade JR, Harney JP, Frye CA (2007) Estradiol-induced conditioned place preference may require actions at estrogen receptors in the nucleus accumbens. *Neuropsychopharmacology* 32:522–530.
- Wise RA (2006) Role of brain dopamine in food reward and reinforcement. *Philos Trans R Soc Lond B Biol Sci* 361:1149–1158.
- Wise RA, Bozarth MA (1984) Brain reward circuitry: four circuit elements “wired” in apparent series. *Brain Res Bull* 12:203–208.
- Wyckhuys T, Staelens S, Van Nieuwenhuyse B, Deleye S, Hallez H, Vonck K, Raedt R, Wadman W, Boon P (2010) Hippocampal deep brain stimulation induces decreased rCBF in the hippocampal formation of the rat. *Neuroimage* 52:55–61.




Figure 1. Combining GLP-1 and estrogen in a subcutaneous injection was effective at reducing body weight and food reward. Conjugation of GLP-1 to estrogen led to a synergistic effect on weight loss (A) and anorexia (B), without inducing malaise as measured by the PICA response (B). The changes in weight and chow intake were associated with a striking suppression of sucrose-driven food reward behavior as indicated by reduced active lever presses (C) and rewards earned (D). Data represent mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ by comparing vehicle to compound injections unless otherwise stated. Differences between groups were calculated with repeated measures ANOVA followed by *post hoc* Bonferroni test (food intake 24h: $F_{(3,45)} = 5.6$, $p < 0.005$; sucrose pellets: $F_{(3,45)} = 24.4$, $p < 0.0001$) or generalized linear model (body weight change: $X^2_{(3)} = 10.4$, $p < 0.05$; active lever presses: $X^2_{(3)} = 45.1$, $p < 0.0001$). $n = 16$.




Figure 2. Central injection of GLP-1-estrogen was sufficient to reduce body weight and food reward. Body weight was significantly reduced after central (intra lateral ventricle) injection of GLP-1 or GLP-1-estrogen conjugate (A). The impact of the treatment on food intake emerged at 24h after injection (B-C). No changes in malaise were noted (C). The sucrose-driven food reward behavior was suppressed by the GLP-1-estrogen conjugate as measured by reduced number of active lever presses (D) and sucrose pellets (E). Importantly the reduced reward behavior was not associated with non-specific reduction in general motor activity (F). Data represent mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ by comparing vehicle to compound injections unless otherwise stated. Differences between groups were calculated with generalized linear model (body weight change: $X^2_{(3)} = 15.4$, $p < 0.005$; ICV, food intake 24h: $X^2_{(3)} = 25.5$, $p < 0.00005$; active lever presses: $X^2_{(3)} = 19.4$, $p < 0.0005$; sucrose pellets: $X^2_{(3)} = 26.8$, $p < 0.0001$). $n = 11-12$.




Figure 3. SPECT-imaging revealed the supramammillary nucleus (SUM), a nucleus largely unexplored in the field of feeding and reward, as the main GLP-1-estrogen target area. Differences in mean tracer uptake in the SUM region (arrow) after injection of GLP-1-estrogen (row A) and GLP-1 (row B) versus vehicle (PBS) and corresponding probability maps (A, B, right column) clearly indicate that blood flow in the SUM was increased specifically after the administration of GLP-1 conjugated to estrogen. Differences in mean tracer uptake were calculated from normalized group data. Increases in mean tracer uptake were displayed in red, decreases in blue. Mean tracer uptake within the SUM/posterior hypothalamus in GLP-1-estrogen, GLP-1, or PBS injected mice (C-D). Hemisections of added global mean normalized data are shown in C. The ROI is highlighted in red including the SUM and posterior hypothalamus and provides a significant increase in tracer uptake after injection of GLP-1-estrogen (** $p < 0.001$) and GLP-1 (* $p < 0.01$) in comparison to PBS injection (D). G: GLP-1; GE: GLP-1-estrogen




Figure 4

Figure 4. The SUM is a direct target site for the impact of the GLP-1-estrogen conjugate on food-motivated behavior. Intra-SUM microinfusion of GLP-1 conjugated to estrogen, but not free GLP-1 or estrogen, reduced body weight (A) and food intake (B) but did not induce malaise measured by kaolin intake (B). Food reward was also potently reduced by intra-SUM microinfusion of both GLP-1 alone and GLP-1 conjugated to estrogen (C-D). Notably the conjugate resulted in a synergistic effect on both parameters of food-reward behavior (active lever presses (C) and number of sucrose rewards earned (D)). Representative tissue section demonstrating SUM injection site (left side) and corresponding rat brain atlas section (right side) (E). In contrast, the same dose of GLP-1-estrogen conjugate injected into the VTA, the well-established target of GLP-1R action of food reward, did not affect food-motivated behavior whereas injection of GLP-1 alone reduces the number of sucrose rewards. **Active lever presses (F)** and number sucrose rewards (G) earned in an operant lever-pressing paradigm after compound injection into the VTA (n = 21). VTA injection site and corresponding rat brain atlas section (H). Data represent mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ by comparing vehicle to compound injections unless otherwise indicated. Differences between groups were calculated with repeated measures ANOVA followed by *post hoc* Bonferroni (food intake 24h: $F_{(3,33)} = 10.0$, $p < 0.0001$; VTA, active lever presses: $F_{(3,60)} = 6.2$, $p < 0.001$; VTA, sucrose pellets: $F_{(3,60)} = 5.6$, $p < 0.01$) or LSD test (body weight change: $F_{(3,33)} = 4.9$, $p < 0.001$; SUM, sucrose pellets: $F_{(3,33)} = 7.3$, $p < 0.001$) or generalized linear model (SUM, active lever presses: $X^2_{(3)} = 17.3$, $p < 0.001$). SN: substantia nigra; SUM: supramammillary nucleus; Aq: aqueduct; cp: cerebral peduncle; ml: medial lemniscus; VTA: ventral tegmental area





Figure 5

Figure 5. GLP-1-estrogen enhances the metabolic benefits when injected into the LH and the NTS. Microinjections of GLP-1-estrogen reduces (A) 24h body weight change and (B) 24h chow intake after compound injection into the LH and NTS (n=21). No beneficial effects were noted on food reward when GLP-1-estrogen was microinjected into the LH and NTS as the number of **active lever presses (C)** and sucrose pellets (D) earned in an operant lever-pressing paradigm was reduced to the same level as GLP-1 alone. LH injection site and corresponding rat brain atlas section (E). Data represent mean \pm SEM. *p<0.05, **p<0.01, ***p<0.001 by comparing vehicle to compound injections unless otherwise stated. Differences between groups were calculated with repeated measures (ANOVA) followed by *post hoc* Bonferroni test (NTS, Food intake 24h: $F_{(3,60)}=4.6$, $p<0.01$; LH, active lever presses: $F_{(3,60)}=6.4$, $p<0.001$; LH, sucrose pellets: $F_{(3,60)}=13.5$, $p<0.001$; NTS, active lever presses: $F_{(3,60)}=6.5$, $p<0.001$; NTS, sucrose pellets: $F_{(3,60)}=10.0$, $p<0.0001$) and Generalized Linear Model (LH, Body weight change: $X^2_{(3)}=72.8$, $p<0.0001$; LH, Food intake 24h: $X^2_{(3)}=98.5$, $p<0.0001$). LH: lateral hypothalamus; DMH: dorsomedial hypothalamus; VMH: ventromedial hypothalamus; Arc: arcuate nucleus



Supplementary Figure 1

Supplementary Figure 1. Differences in mean tracer uptake after injection of GLP-1-estrogen (row A-B) and GLP-1 (row C-D) versus vehicle (PBS) and corresponding probability maps (A-D, right column). The tracer uptake was significantly reduced after GLP-1-estrogen injection in the (A) cingulate area and (B) left primary sensory cortex. After injection of GLP-1 the tracer uptake was found to be reduced in the (C,D) left ectorhinal/entorhinal area and in few voxels within the primary somato sensory cortex and increased in the right amygdala, right cingulate area and left superior colliculus. Differences in mean tracer uptake were calculated from normalized group data. Increases in mean tracer uptake were displayed in red, decreases in blue. GE: GLP-1-estrogen; G: GLP-1

- estrogen (E) and GLP-1 interact to reduce body weight, food intake and food reward
- this interaction can be localized to supramamillary nucleus (SUM)
- and also to the lateral hypothalamus (LH) and nucleus of the solitary tract
- SUM underlies anorexic, weight loss, and reward effects of GLP-1 and E conjugate
- LH underlies only the anorexic and body weight effects the GLP-1 and E conjugate
- SUM is a novel brain area capable of exerting effects on energy balance and reward